Telix Pharmaceuticals (TLX) Other Non-Current Liabilities (2023 - 2025)

Telix Pharmaceuticals (TLX) has reported Other Non-Current Liabilities for 3 consecutive years, with $3.5 million the latest figure, recorded in Q4 2025.

• Quarterly Other Non-Current Liabilities fell 63.84% year-over-year to $3.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.5 million (down 63.84% YoY) and the FY2025 annual result came in at $3.5 million, down 58.77% from the prior year.
• Other Non-Current Liabilities slipped to $3.5 million in Q4 2025 per TLX's latest filing, from $9.7 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for TLX reached as high as $9.7 million in Q4 2024 and fell as low as $3.5 million in Q4 2025.
• A 3-year average of $6.3 million and a median of $5.7 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2024 — Other Non-Current Liabilities surged 72.06% — and 2025, when it sank 63.84%.
• Year by year, Other Non-Current Liabilities stood at $5.7 million in 2023, then jumped by 72.06% to $9.7 million in 2024, then plunged by 63.84% to $3.5 million in 2025.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $3.5 million, $9.7 million, and $5.7 million for Q4 2025, Q4 2024, and Q4 2023 respectively.